Paper of the Month - July, 2012

1 ratings / 5 average

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M et al.; German Breast Group.
In the present study, von Minckwitz et al. investigated the role of neoadjuvant chemotherapy in combination with the well-known monoclonal antibody bevacizumab in HER2-negative breast cancer. This was the GEPARQUINTO (German Preoperative Adriamycin Docetaxel Trial 4) Phase III trial, conducted by the German Breast Group. In the trial, the authors investigated the role of anthracycline/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy in patients with cT2–4 (as well as cT1 node-positive) breast cancer. The study included 1948 patients randomized between November 2007 and June 2010. The primary endpoint was pathological complete response (pCR) defined as pT0 and pN0. In addition to efficacy, the authors investigated the safety profile of the chemotherapy.


Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Powered by NetPolls